-
152024.07
SCM Lifescience’s Atopic Therapy Published in Top Clinical Journal: Gr..
An article on the results of the Phase 1/2 clinical trial of SCM-AGH, a stem cell therapy developed for atopic dermatiti..
-
302024.04
SCM Lifescience, chosen for the 'autoimmune disease stem cell multi-pr..
- Research initiative for the 2024 Pan-Ministry Regenerative Medical Technology Development Project- Results of strategi..
-
112024.04
SCM LifeScience unveils Phase 1·2a results of 'Acute Pancreatitis Stem..
SCM LifeScience's Phase 1 and Phase 2a clinical trials in acute pancreatitis were presented at the prestigious Internati..
-
282022.01
SCM Life Science has completed recruiting patients with phase 2a clini..
SCM Life Science (SCM Life Science, 298060, CEO Sun Uk Song), a company specializing in research and development of cel..
-
282022.01
“SCM Life Science, Expectations for listing and clinical performance o..
On the 15th, Korea Investment & Securities expected full-scale disclosure of clinical results and technology trans..
-
282022.01
SCM Life Science “Results of phase 2 acute pancreatitis and atopic der..
"Next year is a year to prepare for the release of treatments in 2023. Based on the results of phase 2 clinical t..
-
282022.01
Drugs for atopic and acute pancreatitis to start exporting technology
Sun Uk Song, CEO of SCM Life Science, who recently returned to the forefront of management, met with a reporter on the ..
-
282022.01
SCM Life Science completed the initiation meeting for phase 2 clinical..
SCM Life Science (SCM Life Science, Kosdaq 298060, CEO Lee Byung-gun), a development company specializing in cell thera..
-
282022.01
SCM Life Science has obtained a U.S. patent for the composition of dru..
SCM Life Science (SCM Life Science, Kosdaq 298060, CEO Lee Byung-gun), a development company specializing in cell thera..